On June 11, Wuxi WuXi AppTec New Drug Development Co., Ltd. announced on the Hong Kong Stock Exchange that it had filed a lawsuit against the U.S. Department of Defense in the U.S. District Court for the District of Columbia on the 11th local time. The litigation demands include but are not limited to: declaring that the U.S. Department of Defense’s decision to identify WuXi AppTec as a so-called “Chinese Military Corporation (CMC)” is invalid, void, and has no legal effect; revoking and annulling the decision to identify WuXi AppTec as a CMC; and removing WuXi AppTec from the 1260H list.
Source: Hong Kong Stock Exchange website
On June 8, the U.S. Department of Defense announced the latest version of the so-called "Chinese military industrial enterprise list" (i.e., the 1260H list), involving 80 Chinese enterprise groups and nearly 188 related entities.
On the 9th, WuXi AppTec issued an announcement stating: The United States has no basis and this move is a mistake, and it will take all feasible legal actions.
Wuxi WuXi AppTec New Drug Development Co., Ltd. was established on December 1, 2000. Its main business is to provide comprehensive and integrated new drug R&D and production services for the global biopharmaceutical industry.
In recent years, many Chinese technology companies have been included in the so-called "Chinese military industry companies" list by the U.S. Department of Defense. Some of these companies actively use legal means to protect their legitimate rights and interests. In January 2021, Xiaomi was included in the relevant list by the US Department of Defense. After nearly four months of litigation, on May 25, 2021, the U.S. District Court for the District of Columbia issued a final judgment, lifting the U.S. Department of Defense’s determination that Xiaomi is a “Chinese military industrial enterprise.”